Membrane phospholipid is an important reservoir for the generation of bioactive mediators. Cellular phospholipases hydrolyze membrane phospholipid in a structurally specific manner releasing numerous lipid products that are responsible for transmitting diverse signals necessary for the induction of functional responses. Since this is a highly regulated process, the phospholipases are subject to complex mechanisms of activation and presumably deactivation.
The phospholipase A 2 (PLA 2 ) 1 enzymes hydrolyze fatty acid from the sn-2 position of phospholipid with the concomitant production of lysophospholipid. Mammalian cells contain structurally diverse forms of PLA 2 including secretory PLA 2 (sPLA 2 ), calcium-independent PLA 2 , and the 85-kDa cytosolic PLA 2 (cPLA 2 ) (1-4). PLA 2 enzymes function in the digestion of dietary lipid, microbial degradation, and regulation of phospholipid acyl turnover either in a housekeeping role for membrane repair or for the production of inflammatory lipid mediators. The presence of diverse PLA 2 enzymes in mammalian cells provides multiple, differentially regulated pathways for the important process of fatty acid turnover. This review will focus on the biochemical properties and regulation of cPLA 2 , which plays an important role in mediating arachidonic acid release. cPLA 2 shares no homology with other PLA 2 enzymes and is the only well characterized PLA 2 that preferentially hydrolyzes sn-2 arachidonic acid (1, 5, 6) . It should be noted, however, that although sPLA 2 and calcium-independent PLA 2 do not exhibit acyl chain specificity they can also mediate arachidonic acid release depending on the cell type and agonist involved (3, 4) . Arachidonic acid is itself an important regulator of specific cellular processes including regulation of PKC and phospholipase C␥ and modulation of Ca 2ϩ transients (7) (8) (9) (10) (11) . Arachidonic acid can also be converted to potent inflammatory lipid mediators, the eicosanoids. This can occur enzymatically through the lipoxygenase or cyclooxygenase (COX) pathways for the production of leukotrienes, lipoxins, thromboxanes, or prostaglandins (12, 13) . Arachidonic acid is also subject to non-enzymatic, free radical oxidation to bioactive isoprostanes and isoleukotrienes (14, 15) . The important role of arachidonic acid in cellular activation ensures that its levels are tightly controlled. cPLA 2 plays a role in maintaining arachidonate levels and is subject to complex mechanisms of regulation at both the transcriptional and post-translational levels. The involvement of cPLA 2 in lipid mediator production makes it a potentially important pharmacological target for anti-inflammatory drugs. 2 and Regulation of Its Synthesis cPLA 2 is a widely distributed enzyme, and the transcript is expressed at a fairly constant level in all human tissues with somewhat elevated levels in lung and hippocampus (16, 17) . At the cellular level, cPLA 2 is enriched in mononuclear phagocytes but has been found in most cells examined. One notable exception is mature T and B lymphocytes that do not contain cPLA 2 , whereas it is present in thymocytes and immature B cells (18) . This suggests that expression of cPLA 2 may be incompatible with the function of mature lymphocytes. The ubiquitous expression of cPLA 2 is consistent with features of the 5Ј-flanking region of the human gene, which has certain characteristics of a housekeeping promoter in that it has no TATA box (16, 19, 20) . However, unlike many housekeeping promoters, it does not contain a GC-rich region or SP1 sites. The 5Ј-flanking region of the cPLA 2 gene contains a 27-base pair region with a polypyrimidine sequence that is responsible for the basal expression of cPLA 2 (16) . In addition, a 48-base purine/ pyrimidine repeat (CA repeat) appears to confer an inhibitory effect on cPLA 2 gene transcription (20) . By genetic analysis, the human cPLA 2 gene has been localized to chromosome 1q31-41 between markers F13B and D1S74 (16) . However, by structural analysis it has been mapped to chromosome 1q25 (21) . Of interest, the COX 2 gene has also been mapped to the 1q25 region (22) .
Distribution of cPLA
A variety of cytokines and mitogens such as interleukin-1, tumor necrosis factor (TNF), colony-stimulating factor (CSF), epidermal growth factor, c-Kit ligand, and interferon ␥ (IFN␥) have been shown to induce activation and increase synthesis of cPLA 2 in diverse cell models (1) . In WI-38 cells, the increase in cPLA 2 synthesis induced by interleukin-1 correlates with PGE 2 production, and both effects are suppressed by glucocorticoids (23) . In some models, there is coordinate up-regulation of both cPLA 2 and COX 2 (1). The induction of cPLA 2 gene expression by IFN␥ in an epithelial cell line is proposed to occur at the transcriptional level (24) . Consistent with this, the promoter for human cPLA 2 contains a putative IFN␥-activated sequence and IFN␥ response elements (20) . In addition, DNA sequence analysis has revealed two glucocorticoid response elements suggesting that steroids may act to suppress cPLA 2 synthesis at the transcriptional level. There is also evidence for post-transcriptional regulation of cPLA 2 synthesis. In rat mesangial cells, phorbol myristate acetate (PMA), plateletderived growth factor, and serum and epidermal growth factor increase the half-life of cPLA 2 mRNA (25) . An adenosine-uridinerich sequence in the 3Ј-untranslated region of cPLA 2 is thought to be responsible for the instability of the cPLA 2 transcript. Stimulation of cPLA 2 synthesis occurs over hours and results in the prolonged release of arachidonic acid and eicosanoid production.
Catalytic Mechanism
Although cPLA 2 and sPLA 2 catalyze the same reaction their catalytic mechanisms are different. cPLA 2 has multiple enzymatic activities exhibiting in addition to PLA 2 activity high lysophospholipase activity and weak transacylase activity (26 -28) . cPLA 2 can also hydrolyze fatty acid ester of 7-hydroxycoumarin, which has been used as a substrate for continuously monitoring the activity of pure cPLA 2 (29) . Although the transacylase activity may not have physiological relevance, there is evidence that cPLA 2 may function as a lysophospholipase in cells (30) . The coordinate release of sn-2 arachidonic acid followed by the sn-1 fatty acid of diacylphospholipids provides an efficient mechanism for controlling the levels of potentially cytotoxic lysophospholipids. A lysophospholipase with immunological identity to cPLA 2 has recently been purified from bovine brain and exhibits both high activity and selectivity for arachidonoyl-substituted lysophosphatidylcholine (31) . It is suggested that the combined action of brain phospholipase A 1 and this lysophospholipase may provide significant amounts of arachidonic acid in the brain. The transacylase activity provides evidence that the cPLA 2 reaction proceeds by formation of an acyl-enzyme intermediate, either as an acyl-serine or acyl-cysteine. cPLA 2 , which contains 9 cysteine residues, is most stable in the presence of reducing agents (32) . This is in contrast to sPLA 2 enzymes, which are stabilized by disulfide linkages and inactivated by reducing agents. Sulfhydryl-modifying reagents such as iodoacetamide or dithiobisnitrobenzoic acid inactivate cPLA 2 ; however, the cysteine residues are not essential for catalytic activity based on mutagenesis studies (32, 33) . Cys 331 is the residue that is targeted by sulfhydryl-modifying reagents leading to a loss of cPLA 2 activity, which suggests that it is located in a sensitive region of cPLA 2 , possibly near the active site (34, 35) (Fig. 1) .
Several lines of evidence have demonstrated that cPLA 2 contains a serine nucleophile at the active site. NMR analysis of cPLA 2 complexed with an inhibitory trifluoromethylketone analogue of arachidonic acid has revealed a similarity with ␣-chymotrypsin complexed with a peptidyltrifluoromethyl ketone inhibitor (36) . This suggests that the cPLA 2 complex exists as a hemiketal and implicates an active site serine. cPLA 2 shares some sequence homology with phospholipase B from Penicillium notatum, which exhibits both PLA 2 and lysophospholipase activity. Mutation of a conserved serine (Ser 228 ) in cPLA 2 that aligns with a lipase consensus sequence of phospholipase B (Gly-Leu-Ser-Gly-Gly) abolishes both PLA 2 and lysophospholipase activities suggesting a role for Ser 228 in catalysis (33) (Fig. 1 ). The role of Ser 228 as the active site nucleophile has recently been confirmed (37) . When COS cells are cotransfected with COX 1 and mutant forms of cPLA 2 in which Ser 228 is replaced with Ala, Cys, or Thr, they cannot provide arachidonic acid for prostaglandin production in response to A23187 unlike cells transfected with wild type cPLA 2 . Although the S228C mutant cPLA 2 is inactive on phospholipid substrates, it exhibits measurable activity against 7-hydroxycoumarin esters unlike the S228A mutant. These results support an acyl-enzyme intermediate and show that Ser 228 can be replaced by cysteine as the active site nucleophile albeit with reduced catalytic activity. Ser 228 is located in the sequence GLS 228 GS (GXSXS) that is proposed to be an active site consensus sequence for a second group of lipolytic serine esterases (38) . Arg 200 and Asp 549 are also essential for cPLA 2 activity (35) (Fig. 1) . The Asp 549 is comparable with the aspartic acid residue in the catalytic site of the subtilisin proteases. Surprisingly, a histidine residue does not appear to play a role in cPLA 2 action. The mechanism for the involvement of Arg 200 is not known. Thus cPLA 2 contains a novel catalytic center that is responsible for its multiple catalytic activities.
Regulation of cPLA 2 by Calcium cPLA 2 requires calcium for activity; however, unlike sPLA 2 , calcium is necessary for binding cPLA 2 to membrane or phospholipid vesicles rather than for catalysis. cPLA 2 contains an N-terminal calcium-dependent phospholipid binding domain (CaLB) that shares homology with the C2 domains in the conventional isoforms of PKC, Unc-13, phospholipase C␥, synaptotagmin, rabphilin, and p120 GAP to name a few (1) (Fig. 1 ). An increasing number of proteins containing C2 domains are being identified, and many play a role in signal transduction and membrane trafficking (39) . The first C2 domain of synaptotagmin I has been the most extensively characterized and contains 5 aspartate residues that coordinate two calcium ions (40, 41 is a conservative substitution (39) . Calcium at 0.3-1.0 M promotes binding of cPLA 2 to membrane and correlates with the concentration of calcium necessary to stimulate catalytic activity in vitro using phospholipid vesicles as substrate (6, 42) . A fragment of cPLA 2 containing the CaLB domain binds membrane at the same concentrations of calcium required for the intact enzyme, whereas a C-terminal fragment lacking the C2 domain fails to bind membrane but retains catalytic activity against monomeric phospholipid substrates (43) . This work clearly delineates two distinct structural and functional domains of cPLA 2 . The properties of cPLA 2 are consistent with the enzyme being soluble in resting cells at 50 -100 nM calcium and translocating to membrane when intracellular calcium levels increase. It is well documented that arachidonic acid release is triggered in cells by many calcium-mobilizing agonists (1) . In a rat mast cell line, cPLA 2 is cytosolic in resting cells but binds to nuclear membrane in response to calcium ionophore or IgE/antigen (44) . The extent of membrane binding correlates with the amount of arachidonic acid release, which is greater with A23187 than with IgE/antigen. In Chinese hamster ovary cells overexpressing cPLA 2 , calcium ionophore promotes translocation of the enzyme to endoplasmic reticulum and nuclear membrane, which is dependent on the CaLB domain (45) . In contrast, mutation of Ser 505 , the site of MAP kinase (MAPK) phosphorylation, has no effect on cPLA 2 translocation although it abolishes arachidonic acid release. The subcellular localization of cPLA 2 can be dependent on cell density (46) . In confluent endothelial cells, cPLA 2 is cytosolic, but in subconfluent cells most of the cPLA 2 is intranuclear. Exposure of confluent and subconfluent cells to a variety of agonists induces translocation of enzyme to a perinuclear region and the nuclear envelope. In the confluent cells only, cPLA 2 also localizes to intercellular junctions of the plasma membrane. This is the first cell model in which cPLA 2 has been shown to be associated with the plasma membrane. In rat alveolar type II cells, A23187-induced translocation of cPLA 2 to nuclear membrane results in preferential loss of arachidonic acid from this site verifying functional activation of cPLA 2 at the nuclear membrane (47) . Interestingly, 5-lipoxygenase, 5-lipoxygenase activating protein, and COX 2 are also associated with nuclear membrane suggesting that these enzymes form a functional complex for the production of eicosanoids (48) . It also infers that there may be a specific role for eicosanoid production at the nuclear membrane. Preferential targeting of cPLA 2 to the nuclear membrane suggests that there may be specific transport or binding proteins that mediate this process. However, it should be kept in mind that cPLA 2 is also important in mediating eicosanoid production in platelets, which do not contain a nucleus (49) .
Regulation of cPLA 2 by Phosphorylation
In many cell types a stable increase in cPLA 2 activity occurs upon exposure to diverse agonists and can be reversed by phosphatase treatment (1). Agonist-induced phosphorylation of cPLA 2 on serine residues has been verified, and the increased cPLA 2 activity in stimulated cells is attributed to phosphorylation on Ser 505 by MAPK (50 -52) . cPLA 2 has one consensus site for MAPK (PLS 505 P), and phosphorylation of this site in vitro by either p42 or p44 MAPKs increases cPLA 2 activity and induces a characteristic retardation in its electrophoretic mobility or gel shift (53, 54) (Fig. 1) . Phosphorylation of Ser 505 is important in the activation of cPLA 2 in vivo since overexpression of mutant cPLA 2 (S505A) in Chinese hamster ovary cells fails to enhance agonist-induced arachidonic acid release as seen when wild type enzyme is expressed (54) . Other kinases such as PKC and protein kinase A can phosphorylate cPLA 2 in vitro, but this does not result in a significant increase in cPLA 2 activity or a gel shift. However, there is evidence for a role for PKC in the activation of PLA 2 and regulation of arachidonic acid release. PKC activation can play a role by triggering a kinase cascade leading to MAPK activation (55) . There is no evidence at this time that PKC directly phosphorylates cPLA 2 in vivo.
Agonist-induced phosphorylation (gel shift) and activation of cPLA 2 correlates with the activation of p42/p44 MAPKs in many cell models (1). However, it has been shown that phosphorylation of cPLA 2 in lipopolysaccharide-or TNF␣-treated neutrophils and thrombin-stimulated platelets occurs independent of p42 or p44 MAPK activation (56 -58). Since cPLA 2 exhibits a gel shift and 
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increased activity in these models, it suggests that the enzyme is phosphorylated by a proline-directed kinase on Ser 505 , and p38 kinase has recently been implicated (59, 60) . The MAPK homologues p38 and c-Jun N-terminal kinases (JNK) can directly phosphorylate recombinant cPLA 2 in vitro and induce a cPLA 2 gel shift implicating phosphorylation on Ser 505 (61) . However, it has recently been shown in platelets using an inhibitor of p38 kinase that proline-directed phosphorylation of cPLA 2 is not required for mobilization of arachidonic acid in response to thrombin (62) . This suggests that alternative mechanisms are involved in functional activation of cPLA 2 in platelets or that an increase in intracellular calcium alone is sufficient.
Although phosphorylation on Ser 505 is important for cPLA 2 activation in certain cells it is not sufficient for full activation leading to arachidonic acid release (1) . In macrophages, CSF1 is a strong activator of p42/p44 MAPKs and induces phosphorylation and an increase in activity of cPLA 2 . However, CSF1 does not induce arachidonic acid release, but it acts synergistically with calciummobilizing agonists (63) . This suggests that an increase in intracellular calcium, necessary for cPLA 2 translocation, and cPLA 2 phosphorylation, which enhances enzymatic activity, can act together to fully activate cPLA 2 . Interestingly, phosphorylation of cPLA 2 must precede the increase in intracellular Ca 2ϩ to fully activate the enzyme for arachidonic acid release in HER14 cells, and this suggests that cPLA 2 may not be available for phosphorylation if it is first translocated to membrane (64) . However, there is evidence suggesting alternative pathways for regulation of cPLA 2 activation and arachidonic acid release. In macrophages and neutrophils, PMA can induce an increase in phosphorylation and catalytic activity of cPLA 2 as well as arachidonic acid release, and this occurs without an increase in intracellular calcium (51, 65, 66) . However, in other cell models PMA treatment alone induces little arachidonic acid release despite stoichiometric phosphorylation of cPLA 2 and must be combined with a calcium-mobilizing agonist (50) . This suggests that there are novel pathways for regulation of cPLA 2 activation and arachidonic acid release that are cell-specific. Okadaic acid also induces arachidonic acid release in macrophages without increasing intracellular calcium, and this correlates with phosphorylation of a novel site on cPLA 2 (66) . Using cPLA 2 expressed in Sf9 insect cells with baculovirus, phosphorylation sites on cPLA 2 have been identified (52) . cPLA 2 is expressed as an activated phosphoprotein in insect cells where it is constitutively phosphorylated on Ser 505 (52, 67) . However, Sf9 cells overexpressing cPLA 2 exhibit little constitutive release of arachidonic acid, but release can be greatly stimulated by treatment with okadaic acid or calcium ionophore (52) . The phosphorylated residues on the expressed cPLA 2 (52) (Fig. 1) . Ser 437 and Ser 505 are the major phosphorylation sites on the enzyme from unstimulated Sf9 cells. In response to okadaic acid, an increase in phosphorylation preferentially occurs on Ser 727 . A23187 induces only a small increase in labeling of all the sites. There is also evidence that Ser 727 is phosphorylated on cPLA 2 in okadaic acid-treated human monocytes and mouse macrophages. Since okadaic acid does not induce an increase in intracellular calcium the results suggest alternative mechanisms for cPLA 2 There is suggestive evidence that cPLA 2 is also phosphorylated on tyrosine residues. In HEL-30 keratinocytes treated with transforming growth factor ␣, cPLA 2 is detected in antiphosphotyrosine immunoprecipitates (68) . In HeLa S3 cells, immunoprecipitated cPLA 2 is tyrosine-phosphorylated in unstimulated cells, and this increases after treatment with IFN-␣ (69). Interestingly, the tyrosine kinase Jak1 co-immunoprecipitates with cPLA 2 in these cells, and this association is not dependent on IFN treatment. IFN induces arachidonic acid release in these cells, and Jak has been shown to be required for this response. In HeLa S3 cells, cPLA 2 is required for IFN-␣-induced assembly of interferon-stimulated gene factor 3 (69) . The mechanism whereby cPLA 2 mediates this response is not known but is postulated not to involve an arachidonic acid metabolite. The results showing tyrosine phosphorylation of cPLA 2 are intriguing and await confirmation by phosphoamino acid analysis. In several models in which serine phosphorylation of cPLA 2 has been confirmed by phosphoamino acid analysis, no tyrosine phosphorylation of cPLA 2 has been evident. This suggests that the tyrosine phosphorylation is a cell type-and stimulusspecific event.
Role of cPLA 2 in Cytotoxicity cPLA 2 plays a role in mediating several forms of cell injury. In some models the mechanism involved has not been defined whereas in other models, arachidonic acid metabolites are implicated. UV light has been shown to induce activation and increased synthesis of cPLA 2 in keratinocytes and human skin (70) . UVB is a potent inducer of inflammation, and this is thought to be important in its ability to act as a tumor promoter. The production of prostaglandin E 2 after UVB exposure plays an important role in mediating UV erythema, and cPLA 2 is the enzyme responsible for UVinduced prostaglandin E 2 production in human keratinocytes (70) . In human skin, UV-induced erythema correlates with increased synthesis of cPLA 2 , which is mediated by formation of free radicals. UVB irradiation is known to induce a potent oxidative response. UV-induced cPLA 2 synthesis is inhibited by antioxidants, and oxidizing agents can increase cPLA 2 synthesis (71). These results indicate that cPLA 2 is regulated by UV exposure through generation of free radicals and plays an important role in UV-induced injury.
In other models, cellular oxidants have also been shown to activate cPLA 2 . In vascular smooth muscle cells, hydrogen peroxide (H 2 O 2 ) induces serine phosphorylation and activation of cPLA 2 (72) . In this system, cPLA 2 activation and arachidonic acid production are implicated in the induction of c-fos and c-jun and the mitogenic response induced by H 2 O 2 . In contrast, treatment of kidney epithelial cells with H 2 O 2 has been shown to activate cPLA 2 , which contributes to oxidant-induced cytotoxicity (73) . In kidney cells overexpressing either cPLA 2 cPLA 2 is also involved in TNF-induced cell death. Ceramide is an important second messenger that mediates the response to TNF (74) . TNF induces cPLA 2 activation, and the released arachidonic acid is implicated as a regulator of sphingomyelinase activation leading to ceramide production. Importantly, it has been shown that a cPLA 2 -deficient L929 cell line is resistant to TNF-induced toxicity, but this response is restored when cPLA 2 is expressed (75) . However, Fas-induced apoptosis is independent of cPLA 2 since cross-linking this receptor induces cell death equally well in deficient or cPLA 2 -expressing L929 cells (76) . Thus the Fas and TNF type I receptors act through different pathways for inducing apoptosis. Many cell types are not killed by TNF, but some can be rendered susceptible to TNF in conjunction with inhibitors of transcription or translation, and this susceptibility also correlates with the level of cPLA 2 present (77). The role that cPLA 2 plays in mediating TNF␣-induced cell death has not been elucidated.
Conclusion
In conclusion, cPLA 2 is subject to diverse mechanisms of regulation that we are only beginning to understand. cPLA 2 can be quickly activated by post-translational mechanisms to rapidly mobilize arachidonic acid for eicosanoid production. It is also subject to increased synthesis and long term activation leading to prolonged production of lipid mediators. These different mechanisms of regulation are important in determining the diverse functional roles of cPLA 2 . Depending on the tissue or cell type, cPLA 2 
has now
Minireview: Properties and Regulation of Phospholipase A 2 16711 been implicated to function in various cellular responses such as mitogenesis, differentiation, inflammation, and cytotoxicity. cPLA 2 can play a functional role through its ability to trigger arachidonic acid release and eicosanoid production. However, in many cases the mechanisms have not been defined, and it is possible that cPLA 2 may act by affecting local changes in membrane structure or by modulating protein/protein interactions important for signaling mechanisms.
